FENNEC PHARMACEUTICALS INC (FENC)
Health Care · Specialty pharmaceuticals / oncology support therapy · NASDAQ
Commercial-stage biopharma company bringing PEDMARK, the first and only approved drug to prevent cisplatin-induced ototoxicity in pediatric cancer patients, to market.
What FENNEC PHARMACEUTICALS INC does
Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic solutions for pediatric patients. Its primary product is PEDMARK (sodium thiosulfate), which is approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic, solid tumors. The company relies on strategic third-party partnerships to manage international distribution and regulatory approvals outside of the United States.
Themes: pediatric oncology, supportive cancer care, rare disease therapeutics
Fundamentals
- Price$11.40 as of 2026-08-24 close
- Market cap$400M as of 2026-08-24
- 1-year return+31.6% 2025-08-22 close $8.66 → 2026-08-24 close $11.40
- P/En/a negative earnings
- Net margin-12.6% as of 2026-08-24
- Gross margin+92.8% as of 2026-08-24
- ROE-12.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+33.8% as of 2026-08-24
- Revenue CAGR (3y)+207.5% SEC XBRL
- Beta1.01 as of 2026-08-24
- Last reported earnings2026-03-24 SEC EDGAR Form 8-K (Item 2.02)
How FENC compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FENNEC PHARMACEUTICALS INC looks technically
FENNEC PHARMACEUTICALS INC (FENC) is trading 34.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 43 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 10 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 34.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +34.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.54 | $10.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.46 | $8.46 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 9.396. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 43 trading days ago — a "golden cross", a bullish long-term signal | 43 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control | 30.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($10.17 to $13.25) — its "stochastic" reading is 40 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 39.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.25 | $13.25 |
|---|---|---|
| From the 52-week high | it is 14.0% below its 52-week high (its highest price of the past year) | -14.0% |
| Above the 52-week low | it is 101.8% above its 52-week low (its lowest price of the past year) | +101.8% |
| Below the 52-week high | it is 14.0% below its highest point of the past year | 14.0% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $14.99 (set on 2018-04-09) | $14.99 |
| Given back of the 52-week move | over the past year its closes ranged ($5.77 to $12.78), and it has given back roughly a quarter of its rise from last year’s low — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.22 to $8.45. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.7% |
| From the all-time high | it is 23.9% below its all-time high | -23.9% |
| Nearest price level | it is trading 1.1% above a support level at $11.28 — a price it turned at twice since 2026-06-29, most recently on 2026-07-14. Since 2024-08-26 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $0.287 (set on 2015-11-27) | $0.287 |
| Above the all-time low | it is 3872.1% above its all-time low | +3,872% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6668 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6668 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.16 and $12.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.16 – $11.03 – $12.91 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (34.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.19× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 12.8% since the prior reading | +12.8% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 4.2% above the previous close 44 sessions ago and has not traded back through the level it left behind at 9.06 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.2% |
| Gap filled | a 2.2% gap up opened on 2026-08-17 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.8 percentage points (the stock gained 14.1% while the market gained 3.3%) | +10.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 12.4 percentage points (the stock gained 14.8% while the market gained 2.4%) | +12.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.9 percentage points (the stock gained 27.9% while the market gained 11.1%) | +16.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 13.3 percentage points (the stock gained 31.6% while the market gained 18.3%) | +13.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +10.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $8.95 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +27.4% |
|---|
Price levels it has turned at before
FENC last closed at $11.40 on 2026-08-24. Since 2024-08-26 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.28 | Support | 1.1% below the last close | turned there twice · 2026-06-29 to 2026-07-14 |
| $9.85 | Support | 13.6% below the last close | turned there twice · 2025-10-06 to 2026-07-21 |
| $9.41 | Support | 17.5% below the last close | turned there twice · 2025-08-13 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $9.40.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a hammer candle after a decline | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$17.67 range $16.00 – $20.00; median $18.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FENC
- Consensus EPS estimate$0.022 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is a single-product entity, making its business and financial results highly dependent on the successful commercialization of PEDMARK.","Significant history of operating losses and reliance on third-party manufacturers and distribution partners.","Success is subject to complex healthcare regulatory environments, including reimbursement policies, which may limit market access and patient adoption."]
What changed in the latest 10-Q
AI-assisted comparison of FENC's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Added detailed company history: 'a corporation existing under the laws of British Columbia, was originally formed under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014' (filed 2026-05-14)
- Added specific subsidiary details: 'The Company has four wholly owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian corporation, and Fennec Pharmaceuticals (EU) Limited, an Ireland company' (filed 2026-05-14)
- Added statement about clinical study results: 'treatment with PEDMARK ® resulted in an approximate 50% relative reduction in the incidence of cisplatin-induced hearing loss compared to cisplatin alone, without evidence of materially compromised antitumor efficacy' (filed 2026-05-14)
- Added information about Norgine commercial launches during 2025: 'During 2025, Norgine made PEDMARQSI ® commercially available and expects additional launches to occur in 2026 and beyond' (filed 2026-05-14)
- Added specific upfront payment amount in clearer format: 'Fennec received approximately $43 million in upfront consideration' vs. older '$43,200' (filed 2026-05-14)
- Added milestone payment clarification: 'To date, Fennec has not received any milestone payments' (filed 2026-05-14)
- Added detailed U.S. sales force description: 'we sell our product through an experienced field force including Territory Managers' (filed 2026-05-14)
- Added information about Fennec HEARS program: comprehensive description of patient financial and product access support program (filed 2026-05-14)
- Added patent details: 'US 12,311,026 Patent (the "US '026 Patent") covering alternative sodium thiosulfate formulations have been granted in the United States' and additional international patent information (filed 2026-05-14)
- Added reference to Form 10-K filing date: 'filed with the SEC on March 27, 2026' (filed 2026-05-14)
- Removed:
- Removed description 'We are a commercial-stage biopharmaceutical company focused on our only product PEDMARK ®' (was in filed 2025-11-13)
- Removed reference to fiscal year ended December 31, 2024 and March 26, 2025 filing date (filed 2025-11-13)
- Removed reference to 'our plans and strategy' (filed 2025-11-13)
- Removed NCCN clinical practice guidelines reference for AYA Oncology with category 2A recommendation from Overview section (filed 2025-11-13)
- Removed specific PUMA (Pediatric Unique Medicine) reference: 'with up to 8 years of data exclusivity plus 2 years of market protection' (filed 2025-11-13)
- Removed Norgine launch announcement detail: 'Norgine announced the launch of Germany and the U.K. in early 2025' (filed 2025-11-13)
- Removed specific upfront amount notation: '$43,200' and 'approximately $230,000' (filed 2025-11-13)
- Removed reference to 'The Company utilizes medical science liaisons' in U.S. sales context (filed 2025-11-13)
- Removed FDA Orange Book reference formatting: 'FDA Orange Book' vs. 'FDA's Approved Drug Products with Therapeutic Equivalence Evaluations ("FDA Orange Book")' (filed 2026-05-14 provides full format)
- Removed specific May 27, 2025 patent grant date for US '026 Patent (filed 2025-11-13)
- Removed extensive PEDMARK Product Overview section discussing Phase 3 clinical studies, NCCN recommendations details, medical compendia updates, and strategic imperatives (filed 2025-11-13)
- Reworded:
- Changed reference from 'Annual Report on Form 10-K for the fiscal year ended December 31, 2024' to 'for the fiscal year ended December 31, 2025' (filed 2026-05-14)
- Changed 'our plans and strategy for our business' to 'the Company's plans and strategy for its business' (filed 2026-05-14)
- Changed overview structure from brief statement to comprehensive company profile including legal history and subsidiary details (filed 2026-05-14)
- Changed 'focused on our only product' language to 'dedicated to preventing cisplatin-induced ototoxicity' (filed 2026-05-14)
- Changed 'unmet medical need' to 'significant unmet medical need' (filed 2026-05-14)
- Changed upfront consideration notation from unclear '$43,200' to clear '$43 million' (filed 2026-05-14)
- Changed 'may provide us with' to 'may receive' for milestone payments language (filed 2026-05-14)
- Changed 'may provide us with up to approximately $230,000' to 'may receive up to approximately $230 million' with added detail about 'double-digit tiered royalties (up to the mid-twenties)' (filed 2026-05-14)
- Changed patent information structure from narrative about '11,964,018 Patent' to explicit listing as 'US 11,964,018 Patent (the "US '018 Patent")' (filed 2026-05-14)
- Changed 'We are also pursuing additional patent applications' to comprehensive list of 'patent applications covering PEDMARK ® are pending in Brazil, China, the European Patent Office (EPO), Hong Kong, Israel, Korea, Mexico, New Zealand, Singapore, and Thailand' (filed 2026-05-14)
- Changed 'The Company announced an exclusive licensing agreement' to 'we announced that we entered into an agreement' (filed 2026-05-14)
- Changed 'the U.S.' to 'the United States' for consistency in newer filing (filed 2026-05-14)
- Notes:
- The older filing text appears truncated at the end ('In the U.S. and Europe, it is estimated that more than 10,000 pediatric patients may receive platinum-based chemotherapy on an annual basis. The incidenc'), preventing full comparison of the complete Product Overview and subsequent sections.
- Some numerical discrepancies noted (e.g., '$43,200' vs. '$43 million') may reflect typos in the older filing or unit differences, but treated as stated in source texts.
Risk Factors
- Added:
- Newer filing (2026-05-14) presents financial statements as of March 31, 2026 and December 31, 2025, compared to older filing's (2025-11-13) September 30, 2025 and December 31, 2024 dates.
- Newer filing shows PEDMARK product sales of $15,108 thousand for Q1 2026 versus $8,751 thousand for Q1 2025.
- Newer filing reports net income of $201 thousand for Q1 2026 versus net loss of $1,165 thousand for Q1 2025.
- Newer filing shows cash and cash equivalents of $40,179 thousand at March 31, 2026 versus $36,788 thousand at December 31, 2025.
- Newer filing reports total assets of $71,822 thousand at March 31, 2026 versus $70,551 thousand at December 31, 2025.
- Newer filing shows total stockholders' equity of $37,675 thousand at March 31, 2026 versus $35,472 thousand at December 31, 2025.
- Removed:
- Older filing (2025-11-13) presented nine-month and three-month comparative data; newer filing (2026-05-14) presents only three-month data.
- Older filing showed licensing revenue line item of $17,958 thousand for nine months ended September 30, 2024; not present in newer filing's Q1 2026 statement.
- Older filing included term loan of $18,206 thousand and PIK interest of $1,271 thousand as long-term liabilities; newer filing does not show these items.
- Older filing displayed stockholders' deficit of $(4,492) thousand at September 30, 2025 and $(5,872) thousand at December 31, 2024; newer filing shows stockholders' equity (positive) of $37,675 thousand.
- Older filing included operating lease liability - current of $2 thousand at December 31, 2024; not present in newer filing.
- Older filing showed interest expense of $586 thousand for Q3 2025 and $1,772 thousand for nine months 2025; newer filing shows interest expense of $7 thousand for Q1 2026.
- Reworded:
- Older filing labeled balance sheet line as 'Inventory, net' while newer filing labels it 'Inventory'.
- Older filing labeled stockholders' section as 'Stockholders' deficit' at certain dates; newer filing labels it 'Stockholders' equity' reflecting changed financial position.
- Older filing's stockholders' equity statement titled 'Stockholders' Equity (Deficit)' while newer filing titled 'Stockholders' Equity / (Deficit)'.
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs. three and nine months ended September 30, 2025), limiting direct operational comparisons.
- Financial position changes reflect both operational results and timing differences between year-end 2025 (older filing's base) and March 31, 2026 (newer filing's period end).
- Elimination of debt-related line items (term loan, PIK interest, debt discount) in newer filing suggests debt repayment or structural changes not detailed in the excerpted text provided.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($95800) — 1 selling insider
- Last 90 days0 buys · 3 sells ($289492) — 1 selling insider
- Last 180 days0 buys · 5 sells ($418001) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about FENC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding FENC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,885,095
- Reported value $11,593,336
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
FENC had 615,869 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
FENC had 1.76% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.32 days to cover at the same settlement.
- Reported short interest (shares) 615,869
- Short interest (% of shares outstanding) 1.76%
- Prior settlement (shares) 609,189
- Reported change 1.1%
- Days to cover (reported) 5.32
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FENC vs…
FENNEC PHARMACEUTICALS INC is found in…
FENC ranks in…
Frequently asked questions
What does FENNEC PHARMACEUTICALS INC (FENC) do?
Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic solutions for pediatric patients. Its primary product is PEDMARK (sodium thiosulfate), which is approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic, solid tumors.
What sector is FENNEC PHARMACEUTICALS INC (FENC) in?
FENNEC PHARMACEUTICALS INC (FENC) is classified in the Health Care sector. Its industry is Specialty pharmaceuticals / oncology support therapy. It trades on NASDAQ.
Who are FENNEC PHARMACEUTICALS INC's (FENC) competitors?
Notable peers of FENNEC PHARMACEUTICALS INC (FENC) include Amgen, Bristol Myers Squibb, Merck, Pfizer and Novartis. This peer set is informational only — not financial advice.
Is FENNEC PHARMACEUTICALS INC (FENC) overbought or oversold right now?
FENNEC PHARMACEUTICALS INC (FENC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FENC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.